16th International AIDS Conference Toronto, Canada - August 13 - 18, 2006

THE ROLE OF SELENIUM AS ADJUNCT TO HAART AMONG HIV INFECTED INDIVIDUALS WHO ARE ADVANCED IN THEIR DISEASE

Int Conf AIDS. 2006 Aug 13-18;16 Abstract No. MoAb0403

Odunukwe N.N.¹, Onwujekwe D.¹, Ezechi O.O.¹, Ezobi P.¹, Gbajabiamila T.¹, Anyanwu R.¹, Iloka E.¹, Adu R.¹, Nwogbe O.¹, Audu R.¹, Herbertson E.¹, Idigbe E.O.¹, Kanki P.^2
1Nigerian Institute of Medical Research, Clinical Science Division, Yaba, Nigeria, ²Harvard School of Public Health, Boston, United States

BACKGROUND: In developing countries, HIV-1 infection impact on people is devastating. Poor nutrition and HIV-related adverse health outcomes contribute to a vicious cycle that should be slowed down by nutritional supplements. Past studies document decreased levels of antioxidants and selenium in people living with HIV/AIDS. Low serum micronutrient levels in HIV-positive individuals have been associated with immune impairment, disease progression, and increased mortality. This study examined the role of selenium supplement among HIV-positive individuals who were advanced in their disease and are receiving HAART.

METHODS: A follow-up study of all HIV positive individuals with advanced disease recruited for HAART programme between February 2002 and June 2005. One hundred and seventy were on HAART plus Selenium supplement and 170 were on HAART only. Their viral load, CD4 cell count, Haematological and Biochemical indices were analysed at base line and 12 weekly intervals. At each visit adherence and nutritional counselling were given. Data generated were analysed using SPSS statistical software.

RESULTS: Of the 340 subjects recruited, 66% had CD4 cell counts < 50cells/µl. A comparison between those on HAART plus Selenium and those on HAART only showed that the rate of CD4 cell recovery was higher among the HAART plus Selenium group. The median CD4count increments from baseline to 64 weeks were +120cells/µl and +50cells/µl (P=0.02). Less hospital visits for treatment of OIs were recorded for individuals on HAART plus Selenium compare to those on HAART only. Weight gain was significantly higher in Selenium group (P ≤0.004). Median Haemoglobin increments from baseline to 64 weeks were +30g/l and +10g/l (Plus Selenium and non Selenium groups respectively).The median time for undetectable viral load was similar for the two groups (P ≤0.2).

CONCLUSIONS: Selenium supplementation resulted in higher CD4. This supports Selenium supplement as an adjunct to HAART in HIV positive individuals with severe immune suppression.

Download PDF of this abstract.

2006-08-13
MoAb0403

Copyright © 2006 - International AIDS Society (IAS). All information and content relating to the abstracts from the 16th International AIDS Conference, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.

AEGiS is a 501c(3) not-for-profit organization made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, GlaxoSmithKline, the National Library of Medicine, Roche / Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.